DCB Under the Guidance of OCT in STEMI

NCT ID: NCT05680051

Last Updated: 2023-03-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

300 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-01-30

Study Completion Date

2025-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Acute ST segment elevation myocardial infarction (STEMI) has a high disability mortality rate, and timely reperfusion treatment can significantly reduce the mortality of patients. Emergency PCI is the preferred strategy for STEMI treatment recommended by domestic and international guidelines. The long-term existence of stents can never completely avoid the formation of thrombosis in the stents and affect the relaxation and contraction of criminal blood vessels. Drug coated balloon provides a new concept and technology of interventional therapy for coronary artery disease in the form of "intervention without implantation". Through balloon dilation of local blood vessels to release anti proliferative drugs to coronary artery wall and inhibit intimal hyperplasia, it can not only treat serious coronary artery disease, improve coronary blood supply and vascular function, but also not leave permanent implants in the blood vessels; The main pathogenesis of STEMI is thrombosis based on the rupture or erosion of coronary atheromatous plaque. In terms of pathophysiological mechanism, drug coated balloons are also suitable for STEMI patients without obvious thrombosis or severe dissection after full pretreatment. The two-dimensional lumen images obtained by traditional coronary angiography can not directly reflect the vessel wall, so we can not evaluate the actual size of the vessel, plaque characteristics and the effect of intervention through coronary angiography; Optical coherence tomography (OCT) uses near-infrared scanning to produce high-resolution tissue microscopic images with a resolution of up to 10 μ m. It can clearly observe the three-layer structure of coronary artery, find abnormal intima structure, and more clearly identify thrombosis, dissection, plaque erosion or collapse in coronary artery, providing more valuable information for optimizing interventional treatment. Therefore, the application of drug coated balloon under the guidance of OCT in STEMI can provide a more accurate and optimized diagnosis and treatment scheme for STEMI patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute ST-segment Elevation Myocardial Infarction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental group

Drug-coated Balloon (Lepu Medical Technology (Beijing) Co.,Ltd.)

Group Type EXPERIMENTAL

Drug-eluting balloon

Intervention Type DEVICE

Drug eluting balloon was used in the experimental group

Control group

Drug Eluting Stent(Microport Medical)

Group Type ACTIVE_COMPARATOR

Drug-eluting stent

Intervention Type DEVICE

Drug eluting stent was used in the control group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Drug-eluting balloon

Drug eluting balloon was used in the experimental group

Intervention Type DEVICE

Drug-eluting stent

Drug eluting stent was used in the control group

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age 18-75
2. Definitely diagnosed as acute ST segment elevation myocardial infarction according to diagnostic criteria
3. Time of onset ≤ 12h
4. Voluntary signing of informed consent
5. After pretreatment, the culprit vessel participates in stenosis ≤ 30%, no type C (or OCT shows that the dissection involves the middle membrane, and the angle is ≥ 90 degrees) or above, no hematoma, and no obvious thrombus (TIMI thrombus load rating ≤ 2)

Exclusion Criteria

1. Time of onset\>12h
2. Those who are allergic to contrast agents, aspirin tablets and Tigrilol tablets;
3. Active bleeding or recent bleeding history
4. Cardiogenic shock and long-term cardiopulmonary resuscitation;
5. The life span is expected to be less than 12 months
6. Angiography showed left main trunk lesion;
7. Angiography shows patients with in stent restenosis
8. Patients who the investigator thinks may affect the normal progress of the study or cannot cooperate well with the study or may cause obvious risks, such as alcoholics or drug abusers, cancer, serious liver, kidney, lung, endocrine (such as uncontrolled diabetes or thyroid disease), nervous or blood system diseases;
9. Known or suspected pregnancy (baseline ß - hCG pregnancy test must be conducted for women in childbearing period), women in menstrual period.
10. The criminal blood vessel has C-type or above dissection after pretreatment, and there is coronary hematoma.
11. After pretreatment, criminal vessels still have obvious thrombus residues (TIMI thrombus load grade ≥ 3)
12. OCT confirms that the criminal lesion is caused by plaque erosion
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Henan Institute of Cardiovascular Epidemiology

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Fuwai Central China Cardiovascular Hospital

Zhengzhou, Henan, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Junhui Zhang, Dr

Role: CONTACT

+86 0371 58681033

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Junhui Zhang, Dr

Role: primary

0371 58681033

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HenanICE202208

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Drug-eluting Balloon in Acute Myocardial Infarction
NCT00856765 COMPLETED PHASE2/PHASE3
Cohort of STEMI Patients
NCT02822638 COMPLETED
Nitric Oxide in Myocardial Infarction Size
NCT00568061 TERMINATED PHASE2